An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk

[1]  T. Lumley,et al.  gplots: Various R Programming Tools for Plotting Data , 2015 .

[2]  L. Esserman,et al.  An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk , 2013, Breast Cancer Research.

[3]  King-Jen Chang,et al.  Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas , 2012, PloS one.

[4]  A. Kajdacsy-Balla,et al.  The Lymphotactin Receptor Is Expressed in Epithelial Ovarian Carcinoma and Contributes to Cell Migration and Proliferation , 2012, Molecular Cancer Research.

[5]  M. Hetzer,et al.  A change in nuclear pore complex composition regulates cell differentiation. , 2012, Developmental cell.

[6]  D. Absher,et al.  Cancer cell proliferation is inhibited by specific modulation frequencies , 2011, British Journal of Cancer.

[7]  Paul Ellis,et al.  Molecular heterogeneity of triple-negative breast cancer and its clinical implications , 2011, Current opinion in oncology.

[8]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[9]  Dan H. Moore,et al.  Biologic markers determine both the risk and the timing of recurrence in breast cancer , 2011, Breast Cancer Research and Treatment.

[10]  L. Esserman,et al.  A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.

[11]  Lajos Pusztai,et al.  A clinically relevant gene signature in triple negative and basal-like breast cancer , 2010, Breast Cancer Research.

[12]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[13]  L. Esserman,et al.  A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer , 2010, Breast Cancer Research.

[14]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[15]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Wisell,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2010 .

[17]  Lajos Pusztai,et al.  Gene expression profiling of breast cancer , 2009, Breast Cancer Research.

[18]  Jeff Myers,et al.  Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. , 2009, Clinical breast cancer.

[19]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[20]  Trevor Hastie,et al.  Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature , 2008, BMC Cancer.

[21]  Carlos Caldas,et al.  A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer , 2008, Breast Cancer Research.

[22]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[23]  C. Sotiriou,et al.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.

[24]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[25]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[26]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[27]  J. Weidhaas,et al.  Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[29]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[30]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[31]  T. Eberlein.  A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer , 2006 .

[32]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[35]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[36]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.